Location History:
- WeBling, DE (2011)
- Regensburg, DE (2012)
Company Filing History:
2 out of 832,966 Years Active: 2011-2012
Title: The Innovations of Frank-Peter Wachs in CNS Disorders
Introduction
Frank-Peter Wachs is a notable inventor based in Wuppertal, Germany, recognized for his significant contributions to medical technology and therapies targeting central nervous system (CNS) disorders. With a total of two patents to his name, his work focuses on the use of oligonucleotides in pharmaceutical compositions that aim to treat various debilitating illnesses.
Latest Patents
Wachs' latest innovations include groundbreaking patents for "Inhibitors of TGF-R signaling for treatment of CNS disorders." These patents detail the preparation of pharmaceutical compositions that harness oligonucleotides to prevent or treat diseases where neurogenesis and neuroregeneration are beneficial. His research specifically addresses severe conditions such as Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, and many others. These advancements aim to improve the quality of life for patients suffering from these complex and challenging illnesses.
Career Highlights
Throughout his career, Frank-Peter Wachs has been pivotal in exploring innovative therapeutic avenues for CNS disorders. His dedication to advancing medical treatments has led him to seek protection for his inventions through patents, ensuring that his work can contribute positively to the medical field.
Collaborations
Wachs' research has been enriched through collaborations with esteemed colleagues such as Ulrich Bogdahn and Ludwig Aigner. Together, they focus on refining therapeutic strategies and exploring novel approaches to address CNS disorders, thereby enhancing the potential for new treatment options.
Conclusion
Frank-Peter Wachs stands out as a significant inventor in the realm of CNS disorders, paving the way for new therapeutic methodologies. His patents reflect a deep commitment to medical innovation, aimed at tackling some of the most challenging neurological conditions faced today. With ongoing research and collaboration, the future holds promise for further advancements in treating CNS-related diseases.